US 12,144,863 B2
PSMA targeted conjugate compounds and uses thereof
James P. Basilion, Cleveland, OH (US); Xinning Wang, Cleveland, OH (US); and Natalie Walker, Cleveland, OH (US)
Assigned to CASE WESTERN RESERVE UNIVERSITY, Cleveland, OH (US)
Filed by CASE WESTERN RESERVE UNIVERSITY, Cleveland, OH (US)
Filed on Dec. 20, 2021, as Appl. No. 17/555,958.
Application 17/555,958 is a continuation of application No. 17/029,731, filed on Sep. 23, 2020, granted, now 11,202,836.
Application 17/029,731 is a continuation in part of application No. PCT/US2019/023901, filed on Mar. 25, 2019.
Claims priority of provisional application 62/647,267, filed on Mar. 23, 2018.
Prior Publication US 2022/0378926 A1, Dec. 1, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/00 (2006.01); A61K 31/704 (2006.01); A61K 38/05 (2006.01); A61K 47/64 (2017.01); A61P 35/00 (2006.01)
CPC A61K 47/6425 (2017.08) [A61K 31/704 (2013.01); A61K 38/05 (2013.01); A61P 35/00 (2018.01)] 25 Claims
 
1. A method of treating a prostate specific membrane antigen (PSMA) expressing cancer comprising:
administering to a subject with PSMA expressing cancer a therapeutically effective amount of a pharmaceutical composition, the pharmaceutical composition comprising a PSMA targeted conjugate compound that includes general formula (I):

OG Complex Work Unit Chemistry
wherein n and n1 are each independently 1, 2, 3, or 4;
L is an optionally substituted aliphatic or heteroaliphatic linking group;
B has the following formula:

OG Complex Work Unit Chemistry
wherein m is 1, 2, 3, or 4, A is H or

OG Complex Work Unit Chemistry
 and Y and Y1 are each independently selected from at least one of a therapeutic agent or a theranostic agent that is directly or indirectly linked to, respectively, the thiol group of B and the amine group of A.